Novo Nordisk A/S $NVO Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 64.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,744 shares of the company’s stock after selling 56,238 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Novo Nordisk A/S were worth $1,611,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Martin Capital Partners LLC lifted its stake in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas grew its holdings in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after acquiring an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC grew its holdings in Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after acquiring an additional 37,453 shares during the period. Markel Group Inc. grew its holdings in Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after acquiring an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Novo Nordisk A/S during the third quarter worth about $1,294,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NVO opened at $37.62 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a fifty day moving average price of $41.91 and a 200 day moving average price of $49.30. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The stock has a market cap of $167.97 billion, a P/E ratio of 10.84, a P/E/G ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is currently 50.43%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.S. launch of Wegovy HD (7.2 mg) — Novo made the higher‑dose injectable available nationwide, which could boost per‑patient efficacy and sales for its obesity franchise. This is a clear commercial catalyst for near‑term revenue and margin upside. Novo Nordisk launches higher-dose Wegovy in the United States
• Positive Sentiment: Oral Wegovy pill expanding addressable market — reporting and patient interviews indicate the pill is drawing new patients (not just converting injection users), potentially increasing overall GLP‑1 demand and revenue growth opportunities. Novo Nordisk’s Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
• Positive Sentiment: Share‑repurchase programme — Novo Nordisk confirmed repurchases under a DKK 15 billion program, supporting EPS and signaling confidence from management. This is a direct capital‑allocation tailwind for the stock. Novo Nordisk A/S – Share repurchase programme
• Neutral Sentiment: Analyst/valuation commentary and recent volatility — coverage has highlighted share‑price swings and valuation questions after recent moves; investors should watch guidance and uptake metrics to reconcile fundamentals with price. Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Recent Share Price Volatility
• Neutral Sentiment: Short‑term price note — market pieces point out modest intraday gains but that the stock has lagged broader markets recently; useful context but not a direct driver. Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know
• Neutral Sentiment: Ticker/name confusion risk — unrelated firms (e.g., Novo Resources, ticker NVO on other exchanges) are running mining drill stories; be cautious when parsing headlines and data across tickers. Novo to kick off 2026 with maiden Wyloo drill campaign
• Negative Sentiment: Competitive pressure from rivals (e.g., Eli Lilly) — faster rollouts of competing oral GLP‑1s could limit pricing power and market share over time, a key risk as oral options proliferate. Trump’s Iran deadline, the Altman-Musk feud, Novo’s Wegovy pill and more in Morning Squawk

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. Citigroup started coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. CICC Research started coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Four analysts have rated the stock with a Buy rating and twenty have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.